|
A multicenter real-world study reviewing systemic anticancer treatment choices and drop off rates between treatment lines for metastatic renal cell carcinoma in the United Kingdom: In the immunotherapy era. |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
Honoraria - Astellas Oncology; Bayer; Bristol Myers Squibb Foundation; GlaxoSmithKline; Ipsen; Merck; Pfizer |
Consulting or Advisory Role - GlaxoSmithKline; Ipsen; Merck; Pfizer |
Speakers' Bureau - GlaxoSmithKline |
|
|
Honoraria - Bristol Myers Squibb Foundation; Ipsen; Merck; MSD; Novartis; Pfizer |
Consulting or Advisory Role - Eisai |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; Bayer |
|
Dominique Siobhan Parslow |
Honoraria - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; BMS; Merck; Pfizer; Roche; Sanofi/Aventis |
Research Funding - Janssen (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Roche |